Skip to main content

Treatment Clinical Trials for Glioblastoma

Review the glioblastoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 126

Laser Interstitial Thermal Therapy and Hypofractionated Radiation Therapy for the Treatment of Recurrent or Progressive Grade II-IV Glioma
Status: Active
Location: 5 locations
Higher Doses of Hypofractionated Radiation Therapy for the Treatment of Elderly Patients with Glioblastoma, ELITE-GBM Trial
Status: Active
Location: 4 locations
A Study with L19TNF in Combination with Lomustine in Patients with Glioblastoma At Progression or Recurrence
Status: Active
Location: 4 locations
Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Status: Active
Location: 4 locations
Identification of Optimal Atezolizumab Biomarkers before and after Surgical Resection in Patients with Recurrent Glioblastoma, MOAB Trial
Status: Active
Location: 4 locations
DB107-RRV Alone at Resection and then in Combination with DB107-FC and Standard of Care for the Treatment of Newly Diagnosed IDH-mutant Astrocytoma and IDH-wildtype Glioblastoma
Status: Active
Location: 4 locations
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Status: Active
Location: 5 locations
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Status: Active
Location: 4 locations
Carmustine Wafers in Combination with Retifanlimab and Standard of Care Radiation with or without Temozolomide for the Treatment of Newly Diagnosed Glioblastoma or Gliosarcoma
Status: Active
Location: 4 locations
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Status: Active
Location: 5 locations
DB107-RRV in Combination with DB107-FC for the Treatment of Recurrent Glioblastoma Multiforme or Anaplastic Astrocytoma
Status: Active
Location: 3 locations
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
Status: Active
Location: 6 locations
Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioblastoma
Status: Active
Location: 3 locations
Mycophenolate Mofetil in Combination with Standard of Care for the Treatment of Glioblastoma
Status: Active
Location: 3 locations
WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer with Central Nervous System Metastases
Status: Active
Location: 3 locations
Anti-GD2 ADC M3554 in Advanced Solid Tumors
Status: Active
Location: 3 locations
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Status: Active
Location: 3 locations
Troriluzole for the Treatment of Recurrent IDH Wild Type Glioblastoma
Status: Active
Location: 3 locations
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
Status: Active
Location: 5 locations
WP1066 and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma
Status: Active
Location: 2 locations
Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma
Status: Active
Location: 4 locations
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Status: Active
Location: 2 locations
At-Home Cancer Directed Therapy versus in Clinic for the Treatment of Patients with Advanced Cancer, Cancer CARE Beyond Walls
Status: Active
Location: 2 locations
A Vaccine (RNA-LP) for the Treatment of Recurrent Pediatric High-Grade Glioma and Recurrent Osteosarcoma, RNA PRIME Trial
Status: Active
Location: 2 locations
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
Status: Active
Location: 2 locations